Clinical trial · Interventional
Dexmedetomedine and Ketamine in Erector Spinae Block for Postoperative Analgesia Following Mastectomy.
Comparative Study Between Dexmedetomedine and Ketamine in Erector Spinae Plane Block for Postoperative Analgesia Following Modified Radical Mastectomy. A Prospective Randomized Controlled Study.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Persistent pain after breast cancer surgery is frequently observed in more than 60% of patients.The suboptimal management of perioperative pain can lead to the occurrence of persistent breast cancer pain syndrome and phantom breast pain. Dexmedetomidine, a novel α2-agonist with an eight-fold affinity for α2-adrenergic receptors (sedate and analgesic effects) as clonidine, while exerts much less α1-effects., has been found to significantly increase the duration of peripheral nerve blocks, with minimal systemic side effects. Ketamine is a non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptors. It is used for sedation, premedication, induction, and maintenance of general anesthesia. Central, regional, and local anesthetic and analgesic properties have been reported for ketamine. Both can be used through Erector spinae plane block for postoperative pain control.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bupivacaine Hydrochloride | Drug | — | UNRESOLVED |
| Bupivacaine Hydrochloride and dexmedetomedine | Drug | — | UNRESOLVED |
| Bupivacaine Hydrochloride and ketamine | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- ACTIVE_COMPARATOR
- label
- Bupivacaine
- description
- Will receive ultrasound guided ESPB with 0,25% Bupivacaine .
- interventionNames
- Drug: Bupivacaine Hydrochloride
- type
- ACTIVE_COMPARATOR
- label
- Bupivacaine and dexmedetomedine
- description
- Will receive ultrasound guided ESPB with 0,25% Bupivacaine + Dexmedetomidine.
- interventionNames
- Drug: Bupivacaine Hydrochloride and dexmedetomedine
- type
- ACTIVE_COMPARATOR
- label
- Bupivacaine and Ketamine
- description
- will receive ultrasound guided ESPB with 0,25% Bupivacaine + Ketamine.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * ASA I or II . * female aged between 18 to 65. Scheduled for elective modified radical mastectomy under general anesthesia. Exclusion Criteria: * Patient known to have allergy to any of the drugs used in the study. * Infection at injection site. * Coagulation disorders. * severe heart ,liver or kidney disease. * Unwillingness.
References
Publications (1)
- RESULTHasoon J, Urits I, Viswanath O, Dar B, Kaye AD. Erector Spinae Plane Block for the Treatment of Post Mastectomy Pain Syndrome. Cureus. 2021 Jan 12;13(1):e12656. doi: 10.7759/cureus.12656. PMID 33585141